Education
About Us
Working with TipRanks
Follow Us
Cynata Therapeutics Limited (CYYNF)
OTHER OTC:CYYNF
CYYNF Stock Chart & Stats
$0.15
-$0.05(-27.37%)
At close: 4:00 PM EST
$0.15
-$0.05(-27.37%)
Day’s Range― - ―
52-Week Range$0.08 - $0.22
Previous CloseN/A
Volume3.30K
Average Volume (3M)66.00
Market Cap
$58.60M
Enterprise Value$79.33M
Total Cash (Recent Filing)$5.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding237,454,380
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market Cap1.35
Enterprise Value/Revenue42.08
Enterprise Value/Gross Profit42.08
Enterprise Value/Ebitda-8.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$4.89M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt materially reduces financial risk and preserves strategic optionality for a clinical-stage biotech. Over 2–6 months this improves the company's ability to fund development via equity or partnerships, lowers bankruptcy risk, and makes it a more attractive collaborator for licensors.
High Gross MarginsNear-100% gross margins indicate attractive unit economics for cell therapy manufacturing and licensing. Once development and regulatory hurdles are cleared, high margins can support scalable royalties or product sales, enabling durable profitability if fixed R&D and SG&A are controlled.
Proprietary Allogeneic PlatformCymerus's iPSC‑derived allogeneic MSC approach is structurally scalable relative to autologous therapies. A platform that can address multiple immune/inflammatory indications supports licensing opportunities, recurring royalty streams and strategic partnerships, a durable commercial pathway.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow forces reliance on external funding. Over months this elevates dilution risk, can constrain trial progress, and increases execution risk if capital markets or partner interest weaken, threatening program timelines.
Large Operating LossesMeaningful operating losses and negative net margins reflect that current revenues are insufficient to cover R&D and SG&A. Structural improvement requires either successful commercialization or significant partnership deals; absent those, losses will continue to erode equity over time.
No Commercial Revenue / Partnership DependenceBusiness economics are binary: value depends on deals or regulatory approval. Dependence on future partnerships or successful commercialization creates concentrated execution and regulatory risk, making medium-term cashflows uncertain and outcomes highly dependent on third parties.
Cynata Therapeutics Limited News
CYYNF FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest stock price was $0.08 and its highest was $0.22 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is $58.60M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 179 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Feb 19, 2026. The company reported -$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.008.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 237,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in CYYNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.05%
12-Months-Change
Fundamentals
Return on Equity
-138.54%
Trailing 12-Months
Asset Growth
-15.80%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
AnteoTech Ltd
―
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
Ownership Overview
0.25%
Insiders
― Other Institutional Investors
99.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---